The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of 7-day-repeated doses of FYU-981 administered orally to healthy male adults once daily. Participants are randomized to placebo (n=3) or FYU-981 (n=6) in each step. After follow-up examination in the step of lower dose, the next dose is administered.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
18
Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
Subjects randomized to the placebo arm receive placebo.
Japan
Tokyo, Japan
Pharmacokinetics (Cmax: Maximum plasma concentration)
Time frame: 1-, 4-, and 7-day
Pharmacokinetics (Cmin: Minimum plasma concentration)
Time frame: 1-, 2-, 3-, 4-, 5-, 6- and 7-day
Pharmacokinetics (Tmax: Time to reach the peak plasma concentration)
Time frame: 1-, 4-, and 7-day
Pharmacokinetics (T1/2: Elimination half-life of plasma concentration)
Time frame: 1-, 4-, and 7-day
Pharmacokinetics (AUC: Area under the plasma concentration-time curve)
Time frame: 1-, 4-, and 7-day
Pharmacokinetics (Rauc: Accumulation ratio of AUC0-24)
Time frame: 4-, and 7-day
Pharmacokinetics (kel: Elimination rate constant)
Time frame: 1-, 4-, and 7-day
Pharmacokinetics (CLtot/F: Total clearance / Fraction of dose absorbed)
Time frame: 1-, 4-, and 7-day
Pharmacokinetics (Ae: Amount of drug excreted in urine)
Time frame: 9 days
Pharmacokinetics (fe: Fraction of dose excreted in urine)
Time frame: 9 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.